Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices
H.M. Omar Farouque, MBBS, PhD, FRACP,
Jennifer A. Tremmel, MD, SM,
Farshad Raissi Shabari, MD, MPH,
Meenakshi Aggarwal, MD,
William F. Fearon, MD, FACC,
Martin K.C. Ng, MBBS, FRACP,
Mehrdad Rezaee, MD, PhD, FACC,
Alan C. Yeung, MD, FACC and
David P. Lee, MD, FACC*
Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, California
View larger version (13K):
[in a new window]
|
Figure 1 Interval from procedure conclusion to onset of the first clinical manifestation of retoperitoneal hematoma (RPH).
|
|
View larger version (15K):
[in a new window]
|
Figure 2 Simple linear regression plot demonstrating the relationship between body surface area and femoral artery diameter.
|
|
|
